Pamela Clark
Pediatric Endocrinology · Hershey, PANPI 1851364277
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $10,454 of the $15,026 with a category attached, or 69.6%. Novo Nordisk accounts for 88.4% of it on its own, with 25 other manufacturers making up the rest. Reporting peaked in 2021 at $11,453 and has fallen 99.3% since, to $76 in 2025.
Across 120 payments — averaging $125.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$13K
- AbbVie$389
- Azurity Pharmaceuticals, Inc.$223
- Insulet Corporation$159
- Abbott$120
- Pfizer$115
- plus $732 from 20 others
Across 5 payments — averaging $16,542 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$83K
What the payments were for
- Consulting fees$1,87512%
- Speaking & faculty fees$10,45470%
- Travel & lodging$5284%
- Food & beverage$2,17014%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 28 | $13,289 |
| AbbVie | 25 | $389 |
| Azurity Pharmaceuticals, Inc. | 11 | $223 |
| Insulet Corporation | 9 | $159 |
| Abbott | 6 | $120 |
| Pfizer | 7 | $115 |
| Sanofi-aventis U.S. LLC | 5 | $110 |
| Medtronic | 2 | $98 |
| Rhythm Pharmaceuticals, Inc. | 4 | $62 |
| Endo Pharmaceuticals Inc. | 3 | $53 |
| Stryker | 1 | $46 |
| Zealand Pharma US, Inc. | 2 | $44 |
| Kyowa Kirin, Inc. | 2 | $35 |
| Xeris Pharmaceuticals, Inc. | 2 | $31 |
| Eton Pharmaceuticals, Inc. | 2 | $29 |
| BETA Bionics, Inc. | 1 | $24 |
| Ascendis Pharma Endocrinology Inc | 1 | $24 |
| Amneal Pharmaceuticals LLC | 1 | $23 |
| Biomarin Pharmaceutical Inc. | 1 | $23 |
| BD | 1 | $22 |
| Tolmar Pharmaceuticals, Inc. | 1 | $21 |
| Arbor Pharmaceuticals, Inc. | 1 | $20 |
| Neurocrine Biosciences, Inc. | 1 | $20 |
| Regeneron Healthcare Solutions, Inc. | 1 | $19 |
| Ferring Pharmaceuticals Inc. | 1 | $16 |
| Legend Biotech USA Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$15,026 in reported general payments places this provider in the 80th percentile of 80 pediatric endocrinology providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GenotropinSomatropin | 11 | $18,282 |
| Levothyroxine Sodium | 13 | $145 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerGenotropin | $115 | $18,28211 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $23 | $14513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 80 pediatric endocrinology providers in Pennsylvania.
Other pediatric endocrinology in Hershey
- Peter LeeHershey$114K
- Neha PatelHershey$6K
- Kanthi Bangalore KrishnaHershey$539
- Natalie AllenHershey$496
- Raul Ramirez AcevedoHershey$435
- Lina Huerta SaenzHershey$388
- Daniel HaleHershey$323
- Jadranka PopovicPittsburgh$187K
- Michael LevinePhiladelphia$128K
- Craig AlterPhiladelphia$102K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.